白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2012年
11期
674-677
,共4页
宋琳%李玉军%邢晓明%冉雯雯
宋琳%李玉軍%邢曉明%冉雯雯
송림%리옥군%형효명%염문문
淋巴瘤,大B细胞,弥漫性%免疫表型分型%受体,瘦素%STAT3%免疫组织化学
淋巴瘤,大B細胞,瀰漫性%免疫錶型分型%受體,瘦素%STAT3%免疫組織化學
림파류,대B세포,미만성%면역표형분형%수체,수소%STAT3%면역조직화학
Lymphoma,large B-cell,diffuse%Immunophenotyping%Receptors,leptin%STAT3%Immunohistochemistry
目的 探讨瘦素受体(OBR)和磷酸化信号转导与转录激活因子(p-STAT3)在弥漫大B细胞淋巴瘤(DLBCL)中的表达及其与DLBCL免疫表型和临床特征的关系.方法 应用免疫组织化学方法检测80例DLBCL和10例反应性增生淋巴结(RLH)组织中OBR和p-STAT3的表达,并应用免疫组织化学方法检测DLBCL的CD20、CD10、bcl-6、Mum-1免疫标志,根据Hans分型方法将DLBCL分为生发中心B细胞样(GGR)型和非生发中心B细胞样(non-GCB)型.结果 OBR和p-STAT3在DLBCL中的高表达率分别为45.0％(36/80)和28.8％(23/80),在RLH中均低表达,差异均有统计学意义(均P＜ 0.05).p-STAT3在non-GCB型中高表达率为36.8 ％(21/57),明显高于GCB型的8.7％(2/23)(P＜0.05),OBR与DLBCL的免疫表型无关(P＞0.05).OBR及p-STAT3在DLBCL临床Ⅲ、Ⅳ期中的高表达率分别为61.9％(13/21)和38.1％(8/21),高于Ⅰ、Ⅱ期[46.2％(18/39)和25.6％(10/39)],但差异无统计学意义(P＞0.05).OBR和p-STAT3的表达与患者年龄、性别、结外浸润、乳酸脱氢酶水平、B症状及国际预后指数(IPI)评分无关(P＞0.05).OBR和p-STAT3在DLBCL中的表达呈正相关(r=0.232,P=0.039).结论 OBR可激活JAK-STAT信号途径、促进STAT3磷酸化过程,其可能参与DLBCL的发病和non-GCB型DLBCL的进展.
目的 探討瘦素受體(OBR)和燐痠化信號轉導與轉錄激活因子(p-STAT3)在瀰漫大B細胞淋巴瘤(DLBCL)中的錶達及其與DLBCL免疫錶型和臨床特徵的關繫.方法 應用免疫組織化學方法檢測80例DLBCL和10例反應性增生淋巴結(RLH)組織中OBR和p-STAT3的錶達,併應用免疫組織化學方法檢測DLBCL的CD20、CD10、bcl-6、Mum-1免疫標誌,根據Hans分型方法將DLBCL分為生髮中心B細胞樣(GGR)型和非生髮中心B細胞樣(non-GCB)型.結果 OBR和p-STAT3在DLBCL中的高錶達率分彆為45.0％(36/80)和28.8％(23/80),在RLH中均低錶達,差異均有統計學意義(均P＜ 0.05).p-STAT3在non-GCB型中高錶達率為36.8 ％(21/57),明顯高于GCB型的8.7％(2/23)(P＜0.05),OBR與DLBCL的免疫錶型無關(P＞0.05).OBR及p-STAT3在DLBCL臨床Ⅲ、Ⅳ期中的高錶達率分彆為61.9％(13/21)和38.1％(8/21),高于Ⅰ、Ⅱ期[46.2％(18/39)和25.6％(10/39)],但差異無統計學意義(P＞0.05).OBR和p-STAT3的錶達與患者年齡、性彆、結外浸潤、乳痠脫氫酶水平、B癥狀及國際預後指數(IPI)評分無關(P＞0.05).OBR和p-STAT3在DLBCL中的錶達呈正相關(r=0.232,P=0.039).結論 OBR可激活JAK-STAT信號途徑、促進STAT3燐痠化過程,其可能參與DLBCL的髮病和non-GCB型DLBCL的進展.
목적 탐토수소수체(OBR)화린산화신호전도여전록격활인자(p-STAT3)재미만대B세포림파류(DLBCL)중적표체급기여DLBCL면역표형화림상특정적관계.방법 응용면역조직화학방법검측80례DLBCL화10례반응성증생림파결(RLH)조직중OBR화p-STAT3적표체,병응용면역조직화학방법검측DLBCL적CD20、CD10、bcl-6、Mum-1면역표지,근거Hans분형방법장DLBCL분위생발중심B세포양(GGR)형화비생발중심B세포양(non-GCB)형.결과 OBR화p-STAT3재DLBCL중적고표체솔분별위45.0％(36/80)화28.8％(23/80),재RLH중균저표체,차이균유통계학의의(균P＜ 0.05).p-STAT3재non-GCB형중고표체솔위36.8 ％(21/57),명현고우GCB형적8.7％(2/23)(P＜0.05),OBR여DLBCL적면역표형무관(P＞0.05).OBR급p-STAT3재DLBCL림상Ⅲ、Ⅳ기중적고표체솔분별위61.9％(13/21)화38.1％(8/21),고우Ⅰ、Ⅱ기[46.2％(18/39)화25.6％(10/39)],단차이무통계학의의(P＞0.05).OBR화p-STAT3적표체여환자년령、성별、결외침윤、유산탈경매수평、B증상급국제예후지수(IPI)평분무관(P＞0.05).OBR화p-STAT3재DLBCL중적표체정정상관(r=0.232,P=0.039).결론 OBR가격활JAK-STAT신호도경、촉진STAT3린산화과정,기가능삼여DLBCL적발병화non-GCB형DLBCL적진전.
Objective To investigate the expression and clinical significance of leptin receptor (OBR) and phosphorylation of signal transducer and activator of transcription (p-STAT3) in patients with diffuse large B-cell lymphoma (DLBCL).Methods Immunohistochemical analysis was used to detect the expression of OBR and p-STAT3 in 80 patients with DLBCL and 10 patients with reactive lymphoid hyperplasia (RLH).Using a panel of immunohistochemical markers (CD10,bcl-6 and Mum-1),all cases of DLBCL were further divided into two groups,GCB (germinal center B-cell-like) or non-GCB.Results Immunohistochemistry revealed high expression of OBR and p-STAT3 in 45.0 ％ (36/80) and 28.8 ％ (23/80) cases of DLBCL,respectively,and minimal straining in 100.0 ％ (10/10) cases of RLH (P ＜ 0.05).Compared with GCB group (8.7 ％,2/23),non-GCB group had higher p-STAT3 high expression rate (36.8 ％,21/57) (P ＜ 0.05).There was no significant difference in the expression of OBR between these two groups.Compared with clinical stage Ⅰ-Ⅱ [46.2 ％ (18/39) and 25.6 ％ (10/39)],stage Ⅲ-Ⅳ had higher OBR and p-STAT3 high expression rate [61.9 ％ (13/21) and 38.1％ (8/21)] (P ＞ 0.05).The expression of OBR and p-STAT3 were not correlated with age,gender,extranodal infiltrations,LDH level,B-symptoms and IPI(international prognostic index)(P ＞ 0.05).The expression of OBR was positively related with that of p-STAT3 in DLBCL patients (r =0.232,P =0.039).Conclusion OBR could stimulate the JAK-STAT signaling pathway and induces the phosphorylation of STAT3.This may be involved in carcinogenesis and prognosis of DLBCL.
